Long-acting beta2-agonists for chronic obstructive pulmonary disease
about
Inhaled corticosteroids with combination inhaled long-acting beta 2 -agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary diseaseCombined aclidinium bromide and long-acting beta 2 -agonist for COPDNew combinations in the treatment of COPD: rationale for aclidinium-formoterolThe psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature reviewPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims dataStability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions.Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.Agonist binding to β-adrenergic receptors on human airway epithelial cells inhibits migration and wound repair.Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.Persistent disabling breathlessness in chronic obstructive pulmonary disease.The impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approach.An evaluation of early medication use for COPD: a population-based cohort study.Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?β2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility.Pharmacological Management of People Living with End-Stage Chronic Obstructive Pulmonary Disease.Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.Determinants and outcomes of change in physical activity in COPD
P2860
Q24186966-7DD6142D-989C-4A67-BBBB-373BB5B4E6F4Q24187613-AE0C3AB5-8B76-4280-835E-F0D22CB6E8B8Q26765303-E60B1CCD-ACE6-4307-A13F-541DFBD85066Q26992007-D84589AB-DAD7-4F04-B09F-E7E0AAA1D90FQ27348844-574CEEEE-C3FC-41BD-9C5E-5EE3FF4A9ABEQ30822043-5631DD78-EF4D-45C5-917C-494899A9C342Q33698659-FEF42355-62E4-4FEB-8AE7-E4031A7DD5A3Q34609913-19A86AD8-31A7-4CA3-BE05-D6CBBF890B97Q34628637-3E65C79F-0F6C-4DB2-9DAE-4BA14F8E7848Q34753755-A7DD4A2E-D1A0-41AF-B028-E95DA5DBE3C6Q35350962-F5D5B962-0009-4729-AB16-BCDC57B4CCA5Q35538249-EB1C3044-42A8-4742-81D6-FCAAA98369A9Q36188224-EF7357F7-DE35-47BE-B970-D23A84AFE2A3Q36381803-4CF9D1F9-4DD8-485E-BAA6-B69835DF58A1Q37197253-87EFC9D3-5C85-4163-A354-6FB1B4921D2BQ37412885-69642C9B-7E48-4C7B-B924-52262A9962A9Q37456602-B119CA2C-0CC3-49B2-862B-BF923C64312CQ37496424-6FE2D2BB-03E8-4F6C-8BBF-0D14BDCA6215Q37626464-C6B111FF-62ED-49BF-AC97-9F9E795AA7D5Q38352425-ED243E42-D63D-4516-AA76-9A36F509B58CQ38630770-F46491D4-BA82-4C87-B11C-A33CF314328FQ47713313-79A6548C-9382-4ECF-AF3E-0F9AAAFD85CEQ47964378-728B18EA-D6F1-4DEB-85A1-B901E7963C45Q49704801-1A617843-8B3B-4789-8F86-9BCF2BEFB5FBQ58802555-DB00F2C4-B588-4E53-9246-34066FCE21A3
P2860
Long-acting beta2-agonists for chronic obstructive pulmonary disease
description
2013 nî lūn-bûn
@nan
2013 scientific article
@en
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
name
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@ast
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en-gb
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@nl
type
label
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@ast
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en-gb
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@nl
prefLabel
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@ast
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en-gb
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@nl
P2860
P3181
P1476
Long-acting beta2-agonists for chronic obstructive pulmonary disease
@en
P2093
Chris Mavergames
Julia A E Walters
P2860
P304
P3181
P356
10.1002/14651858.CD010177.PUB2
P50
P577
2013-10-15T00:00:00Z